中国临床药学杂志2024，Vol.33Issue(3)：210-214,5.DOI:10.19577/j.1007-4406.2024.03.008
钙调神经蛋白抑制剂联合利妥昔单抗对激素耐药型肾病综合征的疗效
Effect of calmodulin inhibitors combined with rituximab in the treatment of steroid-resistant nephrotic syndrome
唐敏 1李嘉雯 1任增金 2李金坤 3孙增先1
作者信息
- 1. 江苏省连云港市第一人民医院药剂科,连云港 222000
- 2. 江苏省连云港市第一人民医院眼科,连云港 222000
- 3. 江苏省连云港市疾病预防控制中心,连云港 222000
- 折叠
摘要
Abstract
AIM To investigate the clinical efficacy of calmodulin inhibitor(CNI)combined with rituximab in the treatment of steroid-resistant nephrotic syndrome,and to analyze the impact on the micro-inflammatory state of pediatric patients.METHODS 40 pediatric patients with steroid-resistant nephrotic syndrome who were treated in hospital from August 2019 to January 2022 were selected and divided into the study group treated with CNI in combination with rituximab(n=21)and the control group treated with CNI alone(n=19).The remission rate,biochemical indexes,inflammatory indexes and incidence of adverse events were compared between 2 groups at 6 months after treatment.RESULTS After 6 months of treatment,the treatment response rate in the study group was 90.48％,which was higher than 63.16％in the control group,with a statistically significant difference(P＜0.05).The serum total protein and albumin levels increased significantly in both groups,and the serum total protein and albumin levels in the study group were higher than those in the control group(P＜0.05).The levels of cholesterol,blood urea nitrogen and serum creatinine in 2 groups were lower than those before treatment,and the levels of the above indicators in the study group were lower than those in the control group after treatment(P＜0.05).Both levels of C-reactive protein(hs-CRP)and tumour-necrosis factor-α(TNF-α)in 2 groups decreased,and the levels of hs-CRP and TNF-α in the study group were lower than those in the control group(P＜0.05).There was no statistically significant difference in the total incidence of complications between 2 groups(P＞0.05).CONCLUSION In the treatment of steroid-resistant nephrotic syndrome,CNI combined with rituximab exhibis a better effect than that of CNI alone in improving hepatic and renal functions and alleviating the inflammatory state,without increasing the frequency of adverse reactions,which has shown good value in clinical promotion and application.关键词
钙调神经蛋白抑制剂/利妥昔单抗/激素耐药型肾病综合征/炎症状态Key words
calmodulin inhibitor/rituximab/steroid-resistant nephrotic syndrome/microinflammatory state引用本文复制引用
唐敏,李嘉雯,任增金,李金坤,孙增先..钙调神经蛋白抑制剂联合利妥昔单抗对激素耐药型肾病综合征的疗效[J].中国临床药学杂志,2024,33(3):210-214,5.
